Contineum Therapeutics, Inc. Financing Cash Flow
Contineum Therapeutics, Inc. (CTNM) reported Financing Cash Flow of $1.33 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-07-30
- Contineum Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $1.20M, a 1218.68% increase year-over-year.
- Contineum Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $129.00K, a 437.50% increase year-over-year.
- Contineum Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $93.47M, a 14458.41% increase year-over-year.
- Contineum Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $19.11M, a 146861.54% increase year-over-year.
- Contineum Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $112.69M, a 3.38% increase from fiscal 2024.
- Contineum Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $109.00M, a 94.03% increase from fiscal 2023.
- Contineum Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $56.18M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $1.33M 10-Q · filed 2026-07-30 | $94.79M derived: sum of 3 quarters · filed 2026-07-30 | $113.90M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $129.00K 10-Q · filed 2026-05-05 | $93.59M derived: sum of 2 quarters · filed 2026-05-05 | $112.70M derived: sum of 3 quarters · filed 2026-05-05 | $112.79M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $93.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $112.57M derived: sum of 2 quarters · filed 2026-03-05 | $112.66M derived: sum of 3 quarters · filed 2026-07-30 | $112.69M 10-K · filed 2026-03-05 |
| 2025-09-30 | $19.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $19.20M derived: sum of 2 quarters · filed 2026-07-30 | $19.22M 10-Q · filed 2025-10-30 | $19.86M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $91.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $115.00K 10-Q · filed 2026-07-30 | $757.00K derived: sum of 3 quarters · filed 2026-07-30 | $770.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $24.00K 10-Q · filed 2026-05-05 | $666.00K derived: sum of 2 quarters · filed 2026-05-05 | $679.00K derived: sum of 3 quarters · filed 2026-05-05 | $109.04M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $642.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $655.00K derived: sum of 2 quarters · filed 2026-03-05 | $109.02M derived: sum of 3 quarters · filed 2026-03-05 | $109.00M 10-K · filed 2026-03-05 |
| 2024-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $108.38M derived: sum of 2 quarters · filed 2025-10-30 | $108.36M 10-Q · filed 2025-10-30 | $108.04M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $108.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $108.35M 10-Q · filed 2025-08-05 | $108.03M derived: sum of 3 quarters · filed 2025-08-05 | $118.35M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$18.00K 10-Q · filed 2025-05-14 | -$339.00K derived: sum of 2 quarters · filed 2025-05-14 | $9.99M derived: sum of 3 quarters · filed 2025-05-14 | $56.77M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$321.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $10.00M derived: sum of 2 quarters · filed 2025-03-06 | $56.79M derived: sum of 3 quarters · filed 2025-03-06 | $56.18M 10-K · filed 2025-03-06 |
| 2023-09-30 | $10.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $57.11M derived: sum of 2 quarters · filed 2024-11-06 | $56.50M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $46.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $46.17M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$617.00K 10-Q · filed 2024-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |